Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of rare earth compounds for the prevention of kidney stone disease

a rare earth compound and kidney stone technology, applied in the field of preventing or treating kidney stone disease, can solve the problems of not being effective, difficult to take current preventative/treatment methods for urolithiasis, and serious health problems, and achieve the effect of high affinity oxalate binding properties

Inactive Publication Date: 2007-05-24
SHIRE INT LICENSING
View PDF14 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent describes methods for preventing and treating kidney stones by using rare earth salts with high affinity for oxalate binding. The rare earth salt is administered orally to inhibit the formation of kidney stones or to modulate the absorption of oxalate from the gastrointestinal tract. The use of rare earth nontoxic salts as a medicament for treating oxalate-based kidney stones is also described."

Problems solved by technology

This disorder represents a serious health problem.
Current preventative / treatment for urolithiasis are not easy to take and not that effective, e.g., potassium citrate tablets.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of rare earth compounds for the prevention of kidney stone disease
  • Use of rare earth compounds for the prevention of kidney stone disease
  • Use of rare earth compounds for the prevention of kidney stone disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Oxalate Binding Assay

[0028] In order to assess removal of oxalate from a stock solution by lanthanum carbonate, an oxalate binding assay was developed. The assay was based on the phosphate binding assay previously developed for assessing removal of phosphate from a stock solution by lanthanum carbonate (U.S. Pat. No. 5,968,976). Further, the buffer conditions were designed to mimic the conditions present in the stomach and in the small intestine. Briefly, 50 mL of a stock sodium oxalate solution containing 8.5 g / L sodium chloride was adjusted to the desired pH using 5N HCl and the Mettler-Toledo DL58 autotitrator. Various combinations of oxalate and lanthanum carbonate concentrations were tested to determine which would maximize oxalate removal. Prior to the addition of the desired amount of lanthanum carbonate, a 2 mL sample was taken to act as a zero time point sample. The volume of buffer was made up to 50 mL again by adding 2 mL of stock oxalate buffer back to the pH adjusted b...

example 2

Competitive Binding of Oxalate and Phosphate Using Lanthanum Carbonate

[0031] Having found an appropriate concentration combination of oxalate and lanthanum carbonate, competitive binding of oxalate and phosphate by lanthanum carbonate was also explored. The competitive binding assay was based on the phosphate binding assay previously developed for assessing removal of phosphate from a stock solution by lanthanum carbonate (U.S. Pat. No. 5,968,976) as well as the results from the current studies using oxalate. Briefly, a stock solution containing 0.1M anhydrous disodium phosphate, 0.01M sodium oxalate, and 8.5 g / L sodium chloride was prepared. Then, 50 ml of this stock solution was adjusted to either pH 3 or pH 7 using 5N and a Mettler-Toledo DL58 autotitrator. Just prior to the addition of lanthanum carbonate, a 2 ml sample was taken to act as a zero time point sample. The volume of buffer was made up to 50 ml again by adding 2 mL of stock oxalate / phosphate buffer back to the pH ad...

example 3

Oxalate Binding by Additional Rare Earth Compounds

[0033] These data demonstrate that other lanthanide salts can effectively bind oxalate. Yttrium carbonate and cerium carbonate were tested for the ability to bind oxalate as described in Example 1. As shown in FIG. 4, both 0.1 M yttrium carbonate (FIG. 4A) and 0.1 M cerium carbonate (FIG. 4B) were as effective as 0.1 M lanthanum carbonate at binding oxalate at pH 7, but less effective at pH 3.

[0034] Lanthanum, yttrium and cerium rare earth chlorides, and acetates were also assayed at pH 7 for oxalate binding using the assay procedure of Example 1. The assay was similar to that outlined in Example 1 except that after the oxalate solution was adjusted to the desired pH using 5N HCI, the pH was maintained with 1N NaOH. This was necessary since both the chloride compounds as well as the acetate compounds drop the pH of the solution significantly upon there addition. As shown in FIG. 5, at pH 7 lanthanum chloride binds oxalate quite rap...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Conditions such as kidney stones, which are characterized by undesired absorption of oxalate from the intestinal tract are conveniently treated using nontoxic salts of rare earth metal ions.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 10 / 128,783, filed Apr. 22, 2002, which claims priority under 35 U.S.C. § 119(e) from Provisional Application 60 / 285,901, filed 23 Apr. 2001. The contents of these application are incorporated herein by reference.TECHNICAL FIELD [0002] This invention relates to a method of preventing or treating urolithiasis (kidney stone disease) by administering rare earth salts, e.g., Lanthanum salts, to bind dietary oxalate and preventing its absorption into the gastrointestinal tract. BACKGROUND OF THE INVENTION [0003] Nephrolithiasis or urolithiasis is a common disorder defined as the development of stones within the urinary tract such as the kidney stone disease. This disorder represents a serious health problem. Depending on local conditions, between 1 and 14% of the population suffers from this condition. The economic impact of urolithiasis in the U.S. was estimated to be $1.83 bill...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K33/24A61K31/28A61K33/00A61K33/244A61P13/12
CPCA61K33/00Y10S514/891A61P13/00A61P13/04A61P13/12A61K9/0053A61K35/02
Inventor ABRAMS, MICHAEL J.BRIDGER, GARY J.FRICKER, SIMON P.IDZAN, STEFAN R.
Owner SHIRE INT LICENSING